# Lenalidomide and Gemcitabine as First-line Treatment in Patients With Pancreatic Cancer

> **NCT01547260** · PHASE1,PHASE2 · COMPLETED · sponsor: **Maria Liljefors** · enrollment: 34 (actual)

## Conditions studied

- Pancreatic Carcinoma Metastatic
- Pancreatic Ductal Adenocarcinoma

## Interventions

- **DRUG:** Gemzar
- **DRUG:** Revlimid

## Key facts

- **NCT ID:** NCT01547260
- **Lead sponsor:** Maria Liljefors
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-10
- **Primary completion:** 2014-01
- **Final completion:** 2014-11
- **Target enrollment:** 34 (ACTUAL)
- **Last updated:** 2022-08-22

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01547260

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01547260, "Lenalidomide and Gemcitabine as First-line Treatment in Patients With Pancreatic Cancer". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT01547260. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*